|
|
|
| Effect of Tovastaptan assisted with Berprost Sodium in patients with heart failure caused by pulmonary hypertension |
| ZHU Baocheng1 ZHANG Jiaxiu2 |
| 1.Department of Cardiology,Jiujiang First People′s Hospital
2.Department of Respiratory Medicine,Jiujiang First People′s Hospital |
|
|
|
|
Abstract Objective To investigate the effect of Tovastaptan assisted with Berprost Sodium in patients with heart failure caused by pulmonary hypertension.Methods A total of 60 patients with heart failure caused by pulmonary hypertension admitted to Jiujiang First People′s Hospital from June 2020 to January 2021 were selected as the research subjects,and they were divided into control group (30 cases) and research group (30 cases) according to random throwing method.The control group was treated with basic treatment combined with Beprost Sodium,and the study group was treated with Tovaptan on the basis of the control group.Blood sodium,blood potassium,endocrine factors,serum creatinine and adverse reactions were compared between the two groups.Results The disappearance time of edema,relief time of shortness of breath and improvement time of fatigue in the observation group were shorter than those in the control group,and the differences were statistically significant (P＜0.05).Before treatment,there was no significant difference in serum potassium,creatinine and sodium between the two groups (P＞0.05).After treatment,the serum potassium and sodium levels of the two groups were higher than those before treatment,and the serum creatinine was lower than before treatment,and the serum creatinine of the observation group was lower than that of the control group,and the serum sodium and potassium levels were higher than those of the control group,the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Before treatment,there were no significant differences in left ventricular ejection fraction (LVEF) and N-terminal pro brain natriuretic peptide (NT-proBNP) between the two groups (P＞0.05).After treatment,LVEF levels of the two groups were higher than before treatment,NT-proBNP were lower than before treatment,and NT-proBNP of the observation group was lower than that of the control group,LVEF level was higher than that of the control group,the difference was statistically significant (P＜0.05).Conclusion Tovastan combined with Berprost Sodium can effectively improve cardiac function,improve symptom relief time,no serious adverse reactions,and gradually return to normal biochemical indicators in patients with pulmonary hypertension heart failure.
|
|
|
|
|
|
| [1] |
杨宇.缬沙坦与贝前列素钠联合治疗高血压早期肾损伤临床观察[J].中国处方药，2019，17（2）：105-106.
|
| [2] |
陈可冀，吴宗贵，朱明军，等.慢性心力衰竭中西医结合诊疗专家共识[J].心脑血管病防治，2016，16（5）：340-347.
|
| [3] |
王军.托伐普坦辅助治疗对顽固性心力衰竭心功能和血清炎症因子表达的影响[J].临床研究，2020，28（5）：101-103.
|
| [4] |
黄锐.左西孟旦辅助托伐普坦治疗顽固性心力衰竭的有效性及安全性研究[J].中国处方药，2020，18（8）：109-110.
|
| [5] |
孟海娜，谢嘉怡，何微.托伐普坦治疗慢性心力衰竭合并低钠血症的效果[J].中国医科大学学报，2019，48（6）551-554.
|
| [6] |
何丽，徐利莎.托伐普坦辅助治疗对急性心力衰竭患者的HR、SBP、BNP 及24 h 尿量的影响[J].临床医学研究与实践，2018，3（2）：19-21.
|
| [7] |
姚璋璐，董彬.托伐普坦治疗慢性心力衰竭伴低氯血症的临床效果[J].中国当代医药，2021，28（25）：76-79.
|
| [8] |
关芬礼，谭志辉，杨伟钊.托伐普坦治疗慢性肺源性心脏病合并心力衰竭的临床效果[J].中国医学创新，2021，18（35）：126-129.
|
| [9] |
李杰，许军，金子安，等.贝前列素钠对慢性左心衰竭合并肺动脉高压患者的影响[J].安徽医药，2018，22（6）：1155-1158.
|
| [10] |
刘学谦，闫变丽.托伐普坦辅助治疗急性心肌梗死合并心力衰竭的临床效果[J].河南医学研究，2019，28（22）：4091-4092.
|
| [11] |
应少香，黄大岗，罗传毅，等.贝前列素钠治疗慢性心力衰竭合并肺动脉高压的疗效及安全性[J].疑难病杂志，2019，18（1）：27-30.
|
| [12] |
金曼，张洁，殷令妮，等.托伐普坦联合高渗盐水对心力衰竭合并低钠血症患者心功能及血浆B 型利钠肽的影响[J].检验医学与临床，2020，17（12）：119-121.
|
| [13] |
魏凌.托伐普坦治疗慢性心力衰竭的效果分析[J].北方药学，2019，16（12）：23-24.
|
| [14] |
邱乃艳，王珊珊，辛梅.托伐普坦对顽固性心力衰竭伴低钠血症患者临床症状及血浆BNP 和CRP 的影响[J].国际医药卫生导报，2020，26（19）：2869-2871.
|
| [15] |
夏月平，王倩，崔炜.托伐普坦治疗急性心肌梗死后心力衰竭致高钠血症一例[J].中华心力衰竭和心肌病杂志，2020，4（1）：63-65.
|
| [16] |
纪东华.托伐普坦治疗AMI 合并心力衰竭的疗效及对患者血清hs-CRP，NT-proBNP 表达的影响[J].医学信息，2019，32（16）：127-128.
|
| [17] |
盖婉丽，梁云亮，吴琼，等.早期联合应用托拉塞米、托伐普坦及冻干重组人脑利钠肽治疗急性心力衰竭的疗效观察[J].中国循证心血管医学杂志，2019，11（8）：971-974.
|
|
|
|
